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With the purpose of evaluating the behavior of different polymers employed as binders in small-diameter 
pellets for oral administration, we prepared formulations containing paracetamol and one of the following 
polymers: PVP, PEG 1500, hydroxypropylmethylcellulose and methylcellulose, and we evaluated their 
different binding properties. The pellets were obtained by the extrusion/spheronization process and were 
subsequently subjected to fluid bed drying. In order to assess drug delivery, the United States Pharmacopeia 
(USP) apparatus 3 (Bio-Dis) was employed, in conjunction with the method described by the same 
pharmacopeia for the dissolution of paracetamol tablets (apparatus 1). The pellets were also evaluated for 
granulometry, friability, true density and drug content. The results indicate that the different binders used 
are capable of affecting production in different ways, and some of the physicochemical characteristics 
of the pellets, as well as the dissolution test, revealed that the formulations acted like immediate-release 
products. The pellets obtained presented favorable release characteristics for orally disintegrating tablets. 
USP apparatus 3 seems to be more adequate for discriminating among formulations than the basket method.
Uniterms: Binders/evaluation. Pellets/dissolution profile. Pellets/physicochemical characteristics. 
Extrusion/spheronization process. Drug delivery/evaluation.
Com a finalidade de se avaliar o comportamento de diferentes polímeros empregados como aglutinantes 
em pellets de pequeno diâmetro para uso oral foram preparadas formulações contendo paracetamol e um 
dos seguintes polímeros: PVP, PEG 1500, hidroxipropilmetilcelulose e metilcelulose por apresentarem 
diferentes propriedades aglutinantes. Os pellets foram obtidos pelo processo de extrusão/esferonização e 
secagem em leito fluidizado. Para avaliar a liberação do fármaco, empregou-se o método 3 da Farmacopeia 
Americana, também conhecido como Bio-Dis e o método preconizado pela mesma farmacopeia para 
comprimidos de paracetamol. Os pellets foram avaliados, ainda, com relação à granulometria, friabilidade, 
densidade verdadeira e teor. Os resultados indicaram que os diferentes aglutinantes empregados são 
capazes de afetar a produção e algumas das características físico-químicas dos pellets e o ensaio de 
dissolução revelou que as formulações comportam-se como produtos de liberação imediata. Os pellets 
obtidos apresentaram características de liberação favoráveis para a obtenção de comprimidos de liberação 
instantânea. O aparato 3 da Farmacopeia Americana demonstrou ser um método com melhor capacidade 
discriminatória entre as formulações, quando comparado com o método da cesta.
Unitermos: Aglutinantes/avaliação. Pellets/perfil de dissolução. Pellets/características físico-químicas. 
Processo de extrusão/esferonização. Liberação do fármaco.
INTRODUCTION
In recent years, the cost of developing new drugs has 
become a significant hurdle for the pharmaceutical indus-
try, such that innovative product launches are increasingly 
rare. In an attempt to address this issue, research into 
new systems capable of more efficient delivery of dosage 
forms already widely-used in treatment processes is on the 
increase (Mahato, 2007; Qiu et al., 2009).
Accordingly, technologies that promote controlled 
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drug delivery via oral route have increasingly been the 
subject of pharmaceutical research, thus fairly consistently 
fulfilling the necessities of clinical medicine by promoting 
improvements in bioavailability, with extended action and 
reduced toxic side-effects (Pezzini, Silva, Ferraz, 2007; 
Qiu et al., 2009).
Among the different systems/technologies available 
are the so-called pellets, also known as micro-granules, 
which are spherical structures of varying diameters used 
for drug delivery via oral route. They present several tech-
nological advantages compared to other dosage forms, in-
cluding improved flowability properties, greater resistance 
to abrasion (friability) and ease of coating, etc. (Ghebre-
Sellassie, 1989; Santos et al., 2002; Pund et al., 2010).
Pellets can be obtained by means of several different 
processes, of which extrusion followed by spheronization 
and fluid bed drying is the most common. Pellets produced 
in this manner are suitable for coating, and this is the most 
widely-recommended process for producing a modified 
release, multi-particulate dosage form (Ghebre-Sellassie, 
1989; Costa et al., 2003; Costa, Pais, Sousa, 2004; Santos 
et al., 2002; Pund et al., 2010).
Moreover, dissolution testing of solid dosage forms 
is a very useful resource for developing these formula-
tions, since it is an in vitro system capable of predicting 
the release behavior of a dosage form (Costa et al., 2003; 
Doukoumetzidis, Macheras, 2006; Azarmi, Roa, Löben-
berg, 2007).
For controlled release dosage forms, the device des-
ignated by the United States Pharmacopeia as apparatus 
3, also known as “reciprocating cylinders” or Bio-Dis, 
stands out, especially for its ability to subject formulations 
to different pH conditions, thus simulating their passage 
through the human gastrointestinal tract (Klein, Rudolph, 
Dressman, 2002; Yu, Wang, Hussain, 2002; Krämer, 
Grady, Gajendran, 2005).
In order to obtain a controlled-release dosage form, 
the use of agents (excipients) capable of influencing drug 
delivery is essential, thus enabling the acquisition of ad-
equate blood levels for extended periods of time, compared 
to conventional dosage forms (Mahato, 2007).
Accordingly, prior knowledge of the behavior of 
these materials (in general polymers) is useful for predict-
ing the release profile that they will produce, especially 
considering the dynamics of the gastrointestinal tract, 
which subjects the dosage form to different pH conditions 
at different points in its trajectory.
Regardless of the desired release profile for a par-
ticular drug incorporated into a certain pellet formulation, 
the binder is, without a doubt, one of the main components 
of this dosage form. The success of a formulation of this 
type largely depends on this excipient, since a pellet is 
precisely a spherical agglomeration of powders. Therefore, 
the binder will be responsible for pellet integrity and may 
also influence the manufacturing process, dissolution, 
physical stability, among others. (Ghebre-Sellassie, 1989).
Moreover, pellets may be an interesting alternative 
for producing orally disintegrating tablets (ODTs). These 
solid dosage forms are designed to rapidly disintegrate in 
the mouth when in contact with saliva, thus not requir-
ing water for administration. A strategy to mask drug 
taste, without causing any modification in drug release, 
is necessary. Paracetamol is an analgesic drug and its ad-
ministration in ODT form could be applicable in pediatric 
treatment for acute pain, as an alternative to liquid dosage 
forms (AlHusban, Perrie, Mohammed, 2011).
The purpose of this study was to evaluate the im-
pact of the use of different binders in the manufacture of 
small-diameter pellets containing paracetamol by means 
of physicochemical characterization of the formulations 
and an assessment of their dissolution profile by means of 
two different tests employing apparatuses 1 and 3 from the 
United States Pharmacopeia.
MATERIAL AND METHODS
Raw material
All raw material used was of pharmaceutical grade 
and it was used as received. The paracetamol was kindly 
donated by Medley S.A. Indústria Farmacêutica.
The type-101 microcrystalline cellulose, commer-
cially designated Microcel MC101®, and the type 2208 
hydroxypropylmethylcellulose (HPMC) (USP 32), com-
mercially designated as Methocel K100M®, were kindly 
donated by Colorcon do Brasil Ltda.
Formulations
Four formulations, each with a different binder, were 
prepared, as indicated in Table I.
The concentrations of binders we selected were 
those commonly used in our laboratory.
The following procedure was adopted for pellet 
production: after being weighed, the paracetamol and 
the microcrystalline cellulose were mixed in a household 
mixer (± 20 rpm) for around 10 minutes. Then the previ-
ously prepared binder solution was added, little by little, 
and homogenization was continued until the mass reached 
the point where it could be extruded; this was ascertained 
visually. The material was then placed in an APEX® Mul-
tiplex DUA-11 (New Jersey, USA) radial-type extruder, 
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set to ± 3 rpm and fixed with a 0.5 mm mesh. The extruded 
material was then transferred to a CALEVA® Model 250 
spheronizer (Dorset, UK), equipped with a “cross-hatch” 
plate, rotating at 1,000 rpm for about 4 minutes. The pel-
lets were then dried in a HÜTTLIN® Mycrolab fluid bed 
(Steinen, Germany) for 40 minutes, with an input air tem-
perature of 55°C, at a flow rate of 12 m3 per hour.
The process yield was evaluated by comparing the 
theoretical value (the sum of the formulation components, 
except water) with the number of pellets obtained.
Evaluation of the pellets obtained
Granulometry
The batches were granulometrically classified in 
a Haver & Bocker EML Digital Plus test sieve shaker 
(Westfalen, Germany), with an amplitude of 1.0, a stir-
ring time of 2 minutes, a 10-second interval between 
pulses and previously tared test sieves with 0.80, 0.71, 
0.59, 0.42, 0.297, 0.250, 0.210, 0.180 meshes and a 
collecting pan. After classification, the test sieves were 
weighed separately in order to ascertain whether any 
mass was retained in them.
Friability
About 10 g of pellets were weighed and then were 
placed into a Haver & Bocker EML Digital Plus mechani-
cal test sieve shaker (Westfalen, Germany), operating un-
der the same conditions as the granulometry assay. After 
the pellets were classified, the material was gathered up 
and placed in a Logan® FAB-2 friability tester (Somerset, 
USA), together with 200 glass spheres measuring 4.3 mm 
in diameter. The assay time was 8 minutes, totaling 200 
rotations. Then the pellets were removed and again sub-
jected to another granulometric assay. Besides post-assay 
granulometry comparison, the percentage of powder with-
held in the collecting pan was also calculated.
True Density
After weighing about 3 g of pellets directly in the 
sample recipient, which was filled to half way, the material 
was transferred to a Quantachrom Instruments® Ultrapyc-
nometer 1000 gas pycnometer (Boynton Beach, USA).
Morphological Analysis
Images were obtained for each batch using a Fuji 
Film Fine Pix S5100® camera coupled to a Motic SMZ 
168® stereomicroscope, set to 10x magnification. These 
images were then edited with the Image Pro-Plus® version 
4.5.0.29 software program, from which the average diam-
eter, aspect and sphericity parameters were calculated. For 
calibration purposes, an image (obtained under the same 
conditions) of a standard slide containing a straight 1cm 
segment, with 100 divisions, was employed.
Paracetamol content
In order to quantify the paracetamol contained in the 
pellets, a spectrophotometer was used in the UV, in accor-
dance with the following procedure: one sample of each 
pellet formulation was ground up using a porcelain mortar 
and pestle, and from this resulting powder, about 100 mg 
was weighed and then placed in a 100 mL volumetric flask.
Water was added and the flasks were placed in an 
ultrasonic cleaner for 10 minutes. The contents were then 
filtered through a 35 µm Logan 200-1035 filter (Somerset, 
USA). An aliquot of the filtered material was diluted 200 
times and the resulting solution was placed in a 0.5 cm 
quartz cuvette, and then in a Beckman Coulter DU 640® 
spectrophotometer, where a wavelength reading of 
242.5 nm was attained. 
TABLE I - Qualitative and quantitative composition of the pellet formulations produced
COMPONENT 1 2 3 4
Paracetamol (%)
mass (g)
70
140
70
140
70
140
70
140
Microcrystalline cellulose (%)
mass (g)
30
60
30
60
30
60
30
60
PVP K-30* (g) 100.51 --- --- ---
PEG 1500*(g) --- 94.78 --- ---
HPMC* (g) --- --- 37.13 ---
Methylcellulose* (g) --- --- --- 69.16
Water (g) --- --- 37.39 4.23
*In solution form or dissolved in water at 5%
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Dissolution
Bio-Dis
In order to evaluate the dissolution profile of the 
formulations, apparatus 3 from the United States Phar-
macopeia, also known as Bio-Dis, was employed. The 
equipment (Varian Inc., Cary, USA) was configured to 
operate at a temperature of 37 °C with 250 mL of dissolu-
tion medium, coupled to a Varian VK 8000 Dissolution 
Sampling Station (Cary, USA), programmed to collect a 
volume of 5 mL of the medium, at pre-established time 
intervals. 
Initially, the pellets were dissolved in a pH 7.2 phos-
phate buffer and then in HCl 0.1N, since these are used 
in the production of ODT. In this case, the first stage (pH 
7.2 phosphate buffer) is used to simulate the conditions 
encountered by the formulation in the mouth cavity, where 
drug release needs to be minimal (in order to avoid the 
unpleasant taste of the product), and in the second stage 
(HCl 0.1N), the drug needs to be released as fast as pos-
sible, in order to ensure its rapid absorption.
·	 Phosphate buffer pH 7.2 – used in the first row of 
vessels as an initial dissolution medium, with collec-
tion times programmed for 2 and 5 minutes and the 
device operating at 4 oscillations per minute (OPM);
·	 Hydrochloric acid 0.1 N (HCl 0.1 N) – used in the 
second row of vessels, as the stage following the 
phosphate buffer medium, with collection times at 
10, 15, 20, 30 and 45 minutes. In this medium, the 
stirring speed was 10 oscillations per minute.
After weighing (about 100 mg of each formulation), 
the pellets were transferred to the cylinders of the device 
(fitted with a 1.25/177 μm “Poly screen”) and then the as-
say was initiated, whereby the cylinders at 4 OPM were 
immersed in the phosphate buffer for 5 minutes. After this 
time, in accordance with the stipulated programming of 
the device, the cylinders were automatically transferred to 
operate at 10 OPM in the second row of vessels, contain-
ing the acid medium, for the next 40 minutes. The samples 
were quantified with a Beckman Coulter DU 640 spectro-
photometer in a 0.5 cm cuvette at 242.5 nm. Besides the 
dissolved percentage values used to obtain the dissolution 
profiles, the respective dissolution efficiency (DE) values 
were also calculated, in the manner described by Khan & 
Rhodes (1975).
Dissolution profile (apparatus 1 - basket)
A dissolution profile for the formulations in a phos-
phate buffer pH 5.8 was traced, as specified by USP 32 for 
paracetamol tablets, using a VanKel VK 7010 (Cary, USA) 
automated device coupled to a Varian Cary 50 spectropho-
tometer (Cary, USA). As described in the United States 
Pharmacopeia, 900 mL of medium was employed, at a 
temperature of 37 °C, a stirring speed of 75 rpm and collec-
tion times programmed for 2, 5, 10, 15, 20 and 45 minutes.
RESULTS AND DISCUSSION
The technology for obtaining pellets by means of 
the extrusion-spheronization process is, among other fac-
tors, fairly dependent on the excipients employed in the 
formulation, with emphasis on the binder. In fact, pellets 
are agglomerates of powders, which are united precisely 
by the action of these excipients and, therefore, the search 
for an adequate binder for a particular formulation is 
extremely important for the success of the product that 
is to be obtained (Ghebe-Sallassie, 1989; Wlosnewski, 
Kumpugdee-Vollrath, Sriamornsak, 2010).
Accordingly, four different binders dissolved in wa-
ter were tested in this study and the following yield values 
were obtained: 74.39%, 67.05% and 81.73% and 63.22% 
for formulations 1, 2, 3 and 4, respectively. 
These results, all less than 82% are, in fact, due 
largely to two main factors: (a) losses that occurred 
during extrusion in the APEX® device that, because 
of its design, ended up retaining a considerable quan-
tity of mass that should have been extruded; and 
(b) the small size of the batches produced (200 g). The 
greater the quantity produced, the greater the yield, 
because the quantity of mass retained in the extruder is 
always the same, regardless of the volume of material 
processed. Therefore, we considered it improbable that 
the differences registered were due to the use of different 
binders.
In Figure 1, the granulometric distribution of the 
pellets obtained is shown, where it is possible to ascertain 
that, when PEG 1500 was used as a binder, there was 
practically no pellet formation, with a considerable amount 
of the material withheld at the bottom of the set of cloth 
filters. In contrast, the use of PVP resulted in larger and 
not very homogeneous pellets. 
Considering this parameter, the best results were 
obtained with the use of methylcellulose (MC) and HPMC 
and, in both cases, there was a concentration of pellets in 
the 0.42 mm range. Methylcellulose is especially deserv-
ing of note, because more than 80% of it was retained in 
the 0.42 mm cloth filter.
With regards to friability, the results obtained (Fig-
ure 2) indicate that the pellets in which PVP was used as 
a binder were those in which the smallest alteration in 
granulometry was observed after the friability test, thus 
resulting in stronger pellets. For methylcellulose, there 
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was a slight increase in the percentage retained in the 0.42 
mm test sieve, and for the formulation in which HPMC 
was used, there was a greater increase in the percentage 
retained in the same test sieve. However, there was no 
powder formation in any of the three cases, as can be 
ascertained by the quantity of material retained in the col-
lecting pan of the test sieve set.
It is important to emphasize that the method em-
ployed here to evaluate pellet friability differs from that 
normally used and described in literature (Sousa et al., 
2002; Cheboyina, Wyandt, 2008), since a change in the 
granulometry of each formulation has been considered. 
Accordingly, data has been obtained that enables a more 
wide-ranging evaluation of pellet behavior, taking into 
account the wear that the latter may be subject to.
Once density is established, obtained by means of 
a gas pycnometer, it also becomes a very important pa-
rameter in pellet production technology. Density is also a 
means of differentiating pellets from granules, since the 
latter are not subject to densification (by extrusion), con-
trary to pellets, which, generally speaking, have greater 
density. The results (presented in Table II and Figure 3) 
indicate that the type of binder employed in the formula-
tion is capable of causing considerable modifications to 
pellet density, since the values obtained were found to be 
in the range from 1.4199 for the lowest (pellets with MC) 
to 1.4595 (PEG) for the highest value.
Although granulometric analysis is an excellent al-
ternative for evaluating pellet size, visualizing the particles 
with the aid of a microscope is, without a doubt, the best 
alternative for studying pellet morphology. Accordingly, 
it is possible to ascertain not only measurements for the 
FIGURE 1 - Granulometric distribution of the pellets obtained 
using PVP (1), PEG 1500 (2), HPMC (3) and MC (4) as binders.
FIGURE 2 - Granulometric analysis of pellets 1 (PVP K30), 3 (HPMC) and 4 (MC) before and after the friability test.
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pellets formed, but also their shape (Abbaspour, Sadeghi, 
Afrasiabi, Garekani, 2008).
One quite interesting alternative is to use image-
editing software with the capacity to calculate parameters 
pertaining to the shape of the particle under analysis. In 
this study, we used the Image Pro Plus® program, which 
enables, among other parameters, the average diameter 
and sphericity of the pellets to be calculated.
Analysis of these results (Table III) proves that the 
pellets are not perfectly spherical. According to Podczeck, 
Rahman, Newton (1999), a pellet should present values 
of 1.0 for aspect and up to 1.1 for sphericity. Chopra et 
al. (2002) considers that this value may reach up to 1.2. 
None of the formulations studied here conformed to these 
values, and results of more than 1.2 were obtained for both 
parameters. 
Similarly, the average pellet diameter varied consid-
erably, with the smallest particles being obtained for PEG, 
with a diameter of 0.1275 mm, and up to 0.7286 for pellets 
containing MC. For this latter parameter, a value of close to 
0.5 mm was expected, since a screen with this size opening 
was used with the extrusion device to produce these pellets.
This difficulty in obtaining spherical pellets, with 
a diameter close to that of the extruder screen, may be 
explained by two factors:
(a) the reduced size of the pellets: the production of 
dosage forms with reduced sizes is a challenge under 
any circumstances;
(b) the elevated drug content (theoretically 70%) in the 
pellets: microcrystalline cellulose, a component of 
fundamental importance in the production of pellets, 
because of its plasticity, is quite adequate for pellet 
production (Sousa et al., 2002; Sreie et al., 2005); 
however, in the formulations proposed here, this 
component is significantly diluted, as a result of the 
necessity to obtain pellets with a high drug concen-
tration.
It is also necessary to consider that these two factors 
may have had a joint influence; in other words, the sum of 
two unfavorable conditions may have made the attainment 
of pellets with a suitable aspect even more difficult.
Therefore, it was ascertained that, in fact, the mor-
phology of the pellets was significantly influenced by the 
type of binder used. The formulations containing PEG 
and MC are at both extremes, since very small pellets, or 
even powder (average diameter only 0.1275 mm), were 
obtained with the former, while very large pellets, actu-
ally “rod-shaped” (0.7286 mm), were obtained with the 
latter. Both are the result of “weak” and very intensive 
flocculation, respectively, thus preventing separation of 
the pellets that form during spheronization and resulting 
in the “rod shapes”.
Thus, upon analyzing such observations, we can 
state that PVP and HPMC are the binders with the greatest 
potential in the formulations studied herein.
Considering the paracetamol content found in the 
pellets (Table IV), it is possible to make adjustments to 
the quantities of pellets that are to be subjected to the dis-
solution test, thus correcting any distortions that may lead 
to erroneous interpretations with regards to this important 
assay.
One of the dissolution tests executed in this study, 
using apparatus 3 from the United States Pharmacopeia, 
was conceived in order to evaluate the dissolution profile 
of the pellets under changing pH conditions. Although the 
objective of our study was not the attainment of immediate 
release tablets, we cannot disregard the potential of these 
formulations; in other words, small-diameter pellets for 
this type of dosage form. In fact, the production of pel-
TABLE II - True density values obtained for the formulations produced. SD: standard deviation
Formulation Sample 1 Sample 2 Sample 3 Average SD
1 1.4275 1.4270 1.4298 1.4281 0.00149
2 1.4577 1.4595 1.4579 1.4584 0.00098
3 1.4460 1.4438 1.4435 1.4444 0.00136
4 1.4199 1.4174 1.4187 1.4187 0.00125
FIGURE 3 - Graphic representation of the true density values 
obtained for formulations 1 (PVP K30), 2 (PEG), 3 (HPMC) and 
4 (MC). The bars indicate the respective standard deviations.
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TABLE III - Values for average diameter, aspect and sphericity obtained after editing images using the Image Pro Plus® software 
program, for the formulations containing PVP (1), PEG (2), HPMC (3) and MC (4). SD = standard deviation
Parameter 1 2 3 4
Average diameter
± SD
0.7232
0.1820
0.1275
0.0354
0.3282
0.1023
0.7286
0.1587
Aspect
± SD
1.2390
0.0954
1.7182
0.3709
1.4961
0.2103
2.0833
0.8802
Sphericity
± SD
1.4244
0.2002
1.2274
0.1093
1.3440
0.1886
1.5441
0.2435
TABLE IV - Paracetamol content (%), considering the theoretical 
drug value (70%) added to formulations containing PVP (1), 
PEG (2), HPMC (3) and MC (4)
1 2 3 4
1 56.61 63.77 67.09 55.14
2 59.97 60.64 67.67 58.53
3 57.06 62.04 66.13 60.38
Average 57.88 62.15 66.96 58.02
lets is only justifiable in the event that we wish to obtain 
a product with controlled (or modified) release, because 
otherwise the production of traditional tablets would be 
the most rational route to follow, considering the costs 
involved.
Thus, the dissolution profile of the pellets was traced 
under similar conditions to those found for an immediate 
release tablet when administered in the organism. The 
tablet is placed in the oral cavity, and remains in this en-
vironment for around 20-30 seconds, when it completely 
disintegrates after being subject to the action of accu-
mulated saliva, and the resulting suspension is ingested. 
Subsequently, the particles containing the drug are subject 
to the action of gastric acid in the patient’s stomach. 
Therefore, the formulation will be subject to the 
action of saliva, which has a pH of around 7.0 (Pedersen 
et al., 2002) for a short period of time, but with one im-
portant consideration: drug delivery, in this environment, 
must be minimal, or, at the very most, reduced. This is 
because many drugs, including paracetamol, have an un-
pleasant taste and their dissolution in the oral cavity may 
lead to rejection of the product on the part of the patient. 
Total drug delivery would be a disaster in terms of patient 
comfort, however, to some degree, the flavor produced in 
the oral cavity could be masked with the aid of sweeteners 
and flavorings - indispensible components in immediate 
release tablet formulations.
On the other hand, when it reaches the stomach (pH 
1-3), the drug must be quickly delivered so that it can be 
absorbed. Under these conditions, the challenge to over-
come is considerable: to formulate a product capable of re-
taining the drug at a pH of close to 7.0 and then, soon after, 
to promote its rapid delivery in an acidic pH environment.
It is exactly in this type of situation that Bio-Dis 
comes into its own, because it was designed specifically 
for tests in which a change in the pH of the medium is a 
reality (Yu, Wang, Hussain, 2002; Pezzini, Ferraz, 2009; 
Samaha, Shehayeb, Kyriacos, 2009). Thus, the use of a 
pH close to neutral for evaluating the initial minutes of 
dissolution, combined with a very low stirring speed (only 
4 OPM) for a short period of time (5 minutes), followed 
by transposition to a acidic pH value with a higher stirring 
speed (10 OPM), is the precise basis for the aforemen-
tioned conditions.
The dissolution profile obtained in Bio-Dis (Figure 
4) shows that the difference registered in the delivery of 
paracetamol among the evaluated pellets is small and, 
therefore, the binder used does not have any significant ef-
fect on dissolution, at least under the conditions employed 
in this study. On the other hand, what seems to have been 
decisive with regards to dissolution was the granulom-
etry of the pellets, since the formulation containing PVP, 
which presented a DE of 69.11% (Table V) was exactly 
that in which the pellets obtained were the largest in size 
(Figure 1).
Granulometry was also the reason why the pellets 
obtained with PEG 1500 could not be evaluated, with 
regards to dissolution. In this case, as has already been 
discussed, there was considerable formation of powder 
(Figure 1), which made it unfeasible to maintain the par-
ticles in the cylinders of the dissolution equipment (in this 
case the Bio-Dis).
As the pellets were put through a screen for the 
precise purpose of retaining the dosage form inside the 
cylinder, these pellets were deposited at the bottom of the 
dissolution vat, which gave rise to two serious problems: 
(a) the pellets were not properly stirred to promote drug 
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delivery; and (b) when the media were changed, the mate-
rial remained in the previous vessel (in the phosphate buf-
fer) and did not migrate together with the cylinders, to the 
acidic medium. Under these circumstances, a dissolution 
test involving the pellets in which PEG 1500 was used as 
a binder was unfeasible.
Regardless of the problem ascertained for the pellets 
with PEG, it was observed that the formulations containing 
PVP, HPMC and MC behaved like rapid-release formu-
lations (more than 85% of the drug was released within 
15 minutes), which, in fact, indicates the insignificant 
influence of the binders employed in our study.
Thus, when the purpose is to use such pellets to 
produce immediate release tablets, there is one more 
fundamentally important stage: coating, since adequate 
control over drug delivery is essential in this case.
The dissolution of the pellets obtained in the basket 
(apparatus 1), as proposed by USP 32 ed. (Table VI and 
Figure 5), indicated the same tendency as the profile ob-
tained by means of the Bio-Dis: the formulations presented 
very close dissolution profiles. In fact, we observed that, 
with the basket, these values were even closer, almost 
superimposed, with a slight spread for pellets with PVP, 
between 10 and 20 minutes of dissolution.
CONCLUSIONS
From the results obtained in this study, it was ascer-
tained that the use of different binders has a significant ef-
TABLE V - The dissolved percentage (± standard-deviation) obtained for the formulations containing PVP (1), HPMC (3) and MC 
(4) and their respective dissolution efficiency values (DE), in Bio-Dis. n = 3
Time (min) 1 3 4
2 38.64 ± 0.1189 45.85 ± 0.1285 45.69 ± 0.0422
5 67.37 ± 0.1279 70.65 ± 0.0756 75.27 ± 0.0173
10 89.46 ± 0.0250 86.40 ± 0.0743 96.60 ± 0.0374
15 100.05 ± 0.0335 95.39 ± 0.0899 106.89 ± 0.0532
20 104.98 ± 0.0628 98.07 ± 0.1546 112.01 ± 0.0144
30 108.07 ± 0.0407 98.01 ± 0.1501 113.86 ± 0.0401
45 108.89 ± 0.0461 97.45 ± 0.1556 113.40 ± 0.0483
DE (%) 69.11 73.86 73.34
TABLE VI - Dissolved percentage (± standard-deviation) obtained for each formulation and the respective dissolution efficiency 
values (DE) in apparatus 1 (basket). n = 5
Time (min) 1 3 4
2 20.32 ± 0.0545 24.14 ± 0.0344 21.28 ± 0.0383
5 47.79 ± 0.0721 49.10 ± 0.0594 45.84 ± 0.0404
10 68.27 ± 0.0800 71.86 ± 0.0432 70.80 ± 0.0592
15 81.39 ± 0.1184 83.59 ± 0.0483 84.30 ± 0.0635
20 87.56 ± 0.1590 89.89 ± 0.0655 90.27 ± 0.0422
30 92.80 ± 0.1502 92.09 ± 0.0896 95.88 ± 0.0549
45 90.93 ± 0.0816 90.14 ± 0.0621 100.49 ± 0.0660
DE (%) 68.56 69.31 72.60
FIGURE 4 - Dissolution profiles obtained in Bio-Dis for 
formulations 1, 3 and 4. Media: up to 5 minutes - phosphate 
buffer pH 7.2 and HCl 0.1 N added to the dissolution vat after 
5 minutes. n=3.
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FIGURE 5 - Dissolution profiles obtained in apparatus 1 (basket) 
for formulations 1, 3 and 4. Medium: phosphate buffer pH 5.8. 
n=5.
fect on the production of small-diameter pellets containing 
paracetamol, as well as on some of their physicochemical 
characteristics, especially density. However, with regards 
to dissolution, evaluated by two different methods, the 
formulations all had immediate release characteristics. It 
was also ascertained that the dissolution test in Bio-Dis 
seems to be the most adequate for discriminating among 
formulations, when compared to the basket method.
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